In this episode of EASL Studio, a very special interview with Prof. Stephan Urban talking about his journey of the discovery and development of the first HBV/HDV entry inhibitor.
- Where did the story begin and what were the major breakthroughs and challenges?
- What are the mechanisms of viral entry inhibitors and how it differs from direct acting antivirals mode of action?
- How does it impact the future of HBV/HDV treatment landscape?
This project has been made possible with the provision of a financial grant from Gilead Sciences Europe Ltd.
EASL has received no input from Gilead with regard to the content of this programme.
ℹ️ Please click here to access the podcast version of this EASL Studio episode.